Personalized tumor combination therapy optimization using the single-cell transcriptome

被引:7
|
作者
Tang, Chen [1 ]
Fu, Shaliu [1 ,2 ,3 ]
Jin, Xuan [1 ]
Li, Wannian [1 ]
Xing, Feiyang [1 ]
Duan, Bin [2 ,3 ]
Cheng, Xiaojie [1 ]
Chen, Xiaohan [1 ]
Wang, Shuguang [1 ]
Zhu, Chenyu [1 ]
Li, Gaoyang [2 ,3 ]
Chuai, Guohui [1 ]
He, Yayi [4 ]
Wang, Ping [5 ]
Liu, Qi [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构
[1] Tongji Univ, Tongji Hosp, Minist Educ, Sch Life Sci & Technol,Frontier Sci Ctr Stem Cell, Shanghai, Peoples R China
[2] Tongji Univ, Translat Med Ctr Stem Cell Therapy, Shanghai 200092, Peoples R China
[3] Tongji Univ, Shanghai East Hosp, Frontier Sci Ctr Stem Cell Res, Inst Regenerat Med,Sch Life Sci & Technol,Bioinfor, Shanghai 200092, Peoples R China
[4] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Canc Inst,Dept Med Oncol, Shanghai 200433, Peoples R China
[5] Tongji Univ, Shanghai Peoples Hosp 10, Canc Ctr, Shanghai, Peoples R China
[6] Zhejiang Lab, Res Inst Intelligent Comp, Hangzhou 311121, Peoples R China
[7] Shanghai Res Inst Intelligent Autonomous Syst, Shanghai 201210, Peoples R China
关键词
Single-cell RNA-seq; Immunotherapy; Combination therapy optimization; Bipartite graph; Computational pipeline; Web server; Precision medicine; DRUG-COMBINATIONS; CANCER; LANDSCAPE; BLOCKADE; DYNAMICS; GENOME; BREAST; ATLAS; COLON;
D O I
10.1186/s13073-023-01256-6
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
BackgroundThe precise characterization of individual tumors and immune microenvironments using transcriptome sequencing has provided a great opportunity for successful personalized cancer treatment. However, the cancer treatment response is often characterized by in vitro assays or bulk transcriptomes that neglect the heterogeneity of malignant tumors in vivo and the immune microenvironment, motivating the need to use single-cell transcriptomes for personalized cancer treatment.MethodsHere, we present comboSC, a computational proof-of-concept study to explore the feasibility of personalized cancer combination therapy optimization using single-cell transcriptomes. ComboSC provides a workable solution to stratify individual patient samples based on quantitative evaluation of their personalized immune microenvironment with single-cell RNA sequencing and maximize the translational potential of in vitro cellular response to unify the identification of synergistic drug/small molecule combinations or small molecules that can be paired with immune checkpoint inhibitors to boost immunotherapy from a large collection of small molecules and drugs, and finally prioritize them for personalized clinical use based on bipartition graph optimization.ResultsWe apply comboSC to publicly available 119 single-cell transcriptome data from a comprehensive set of 119 tumor samples from 15 cancer types and validate the predicted drug combination with literature evidence, mining clinical trial data, perturbation of patient-derived cell line data, and finally in-vivo samples.ConclusionsOverall, comboSC provides a feasible and one-stop computational prototype and a proof-of-concept study to predict potential drug combinations for further experimental validation and clinical usage using the single-cell transcriptome, which will facilitate and accelerate personalized tumor treatment by reducing screening time from a large drug combination space and saving valuable treatment time for individual patients. A user-friendly web server of comboSC for both clinical and research users is available at www.combosc.top. The source code is also available on GitHub at https://github.com/bm2-lab/comboSC.
引用
收藏
页数:21
相关论文
共 50 条
  • [21] A single-cell transcriptome and surface proteome analysis of the tumor and immune microenvironment in DLBCL
    Yuasa, Mitsuhiro
    Koya, Junji
    Saito, Yuki
    Kogure, Yasunori
    Ito, Yuta
    Shingaki, Sumito
    Murakami, Koichi
    Yamaguchi, Kentaro
    Ennishi, Daisuke
    Tajima, Fumihito
    Kataoka, Keisuke
    CANCER SCIENCE, 2023, 114 : 2087 - 2087
  • [22] Integration of single-cell transcriptome and chromatin accessibility and its application on tumor investigation
    Yang, Chunyuan
    Jin, Yan
    Yin, Yuxin
    LIFE MEDICINE, 2024, 3 (02):
  • [23] Early lung carcinogenesis and tumor microenvironment observed by single-cell transcriptome analysis
    Kim, Eun Young
    Cha, Yoon Jin
    Lee, Sang Hoon
    Jeong, Sukin
    Choi, Yong Jun
    Moon, Duk Hwan
    Lee, Sungsoo
    Chang, Yoon Soo
    TRANSLATIONAL ONCOLOGY, 2022, 15 (01):
  • [24] A winning single-cell combination
    Tal Nawy
    Nature Methods, 2018, 15 : 859 - 859
  • [25] Deep characterization of tumor infiltrating leukocytes using a combination of flow cytometry and single-cell multiomics
    Shi, Xiaoshan
    Nakamoto, Margaret
    Middlebrook, Aaron
    Huang, Wei
    Lo, Evelyn
    Neuhoefer, Patrick Thomas
    Bornheimer, Scott
    Ghanekar, Smita
    JOURNAL OF IMMUNOLOGY, 2021, 206
  • [26] A winning single-cell combination
    Nawy, Tal
    NATURE METHODS, 2018, 15 (11) : 859 - 859
  • [27] Single-cell profiling of NSCLC tumor treated with Durvalumab and in combination with Tremelimumab
    Shrestha, Yashaswi
    Zhang, Qu
    Cheng, Li
    Halpin, Rebecca
    Higgs, Brandon W.
    Raja, Rajiv
    Streicher, Katie
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] Single-Cell Transcriptome Profiling Reveals Tumor Cell Heterogeneity and Immunosuppressive Microenvironment in Waldenstrom Macroglobulinemia
    Sun, Hao
    Fang, Teng
    Wang, Tingyu
    Yu, Zhen
    Gong, Lixin
    Wei, Xiaojing
    Qiu, Lugui
    Hao, Mu
    BLOOD, 2022, 140 : 11872 - 11872
  • [29] Tumor heterogeneity and therapy resistance analyzed at the single-cell level
    Colaprico, Antonio
    Petralia, Francesca
    Papaleo, Elena
    Gavaert, Olivier
    Chen, Xi
    Szkudlarek, Karol
    Wiznerowicz, Maciej
    CANCER RESEARCH, 2019, 79 (13)
  • [30] Measurement of tumor hypoxia using single-cell methods
    Olive, PL
    Aquino-Parsons, C
    SEMINARS IN RADIATION ONCOLOGY, 2004, 14 (03) : 241 - 248